论文信息 - The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

7511Background: Cerdulatinib is a selective, potent inhibitor of SYK, JAK1, JAK3, and TYK2. Preclinical and clinical data suggest that combined SYK/JAK inhibition may have activity in B- and T-cell...